Global Rabies Vaccine for Humans Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rabies Vaccine for Humans Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rabies Vaccine is an immunization drug used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
Rabies Vaccine for Humans report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rabies Vaccine for Humans market is projected to reach US$ 1343.8 million in 2034, increasing from US$ 1056 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Demand from Pre-exposure prophylaxis and Post-exposure prophylaxis are the major drivers for the industry.
Global Human Rabies Vaccine market leaders include Chengda Bio, Bharat Biotech, Bavarian Nordic, Sanofi-Pasteur, etc. All of the above hold over 65 percent market share.
Asia-Pacific is the largest consumption area, with a consumption market share close to 60%. Besides, North Americas is the second largest consumption area with a consumption market share of over 15%.
The classification of Human Rabies Vaccine includes Vero Cell, BHK, Chick Embryo Cell, Human Diploid Cells, and Others. In addition, the proportion of Vero Cell rabies vaccines is about 85%.
Human Rabies Vaccine is widely used for Pre-exposure and Post-exposure. The segment of Human Rabies Vaccine used for Post-exposure and the market share is over 71% of the share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rabies Vaccine for Humans market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Segment by Type
Preventative Vaccine
Emergency Rabies Vaccine
Pre-exposure prophylaxis
Post-exposure prophylaxis
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rabies Vaccine for Humans market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rabies Vaccine for Humans, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rabies Vaccine for Humans industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rabies Vaccine for Humans in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rabies Vaccine for Humans introduction, etc. Rabies Vaccine for Humans Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rabies Vaccine for Humans market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies, before or after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
Rabies Vaccine for Humans report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rabies Vaccine for Humans market is projected to reach US$ 1343.8 million in 2034, increasing from US$ 1056 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Demand from Pre-exposure prophylaxis and Post-exposure prophylaxis are the major drivers for the industry.
Global Human Rabies Vaccine market leaders include Chengda Bio, Bharat Biotech, Bavarian Nordic, Sanofi-Pasteur, etc. All of the above hold over 65 percent market share.
Asia-Pacific is the largest consumption area, with a consumption market share close to 60%. Besides, North Americas is the second largest consumption area with a consumption market share of over 15%.
The classification of Human Rabies Vaccine includes Vero Cell, BHK, Chick Embryo Cell, Human Diploid Cells, and Others. In addition, the proportion of Vero Cell rabies vaccines is about 85%.
Human Rabies Vaccine is widely used for Pre-exposure and Post-exposure. The segment of Human Rabies Vaccine used for Post-exposure and the market share is over 71% of the share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rabies Vaccine for Humans market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Sanofi
GlaxoSmithKline
Merck
Chengda
Yisheng
Prcmise
VACN
Changsheng
BCHT
Hissen
Segment by Type
Preventative Vaccine
Emergency Rabies Vaccine
Segment by Application
Pre-exposure prophylaxis
Post-exposure prophylaxis
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rabies Vaccine for Humans market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rabies Vaccine for Humans, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rabies Vaccine for Humans industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rabies Vaccine for Humans in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rabies Vaccine for Humans introduction, etc. Rabies Vaccine for Humans Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Rabies Vaccine for Humans market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices